acylated peptide raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-01-11. Anything still debated is marked as such rather than presented as settled.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released by intestinal L cells after food intake. The natural hormone acts on pancreatic and central receptors but is degraded within minutes by dipeptidyl peptidase-4 and other peptidases. Semaglutide belongs to the class of long-acting GLP-1 receptor agonists, a group distinguished by structural changes that slow breakdown and extend circulation time. Its development followed earlier short-acting analogues and reflects a general strategy in peptide drug design: preserve receptor activity while blocking proteolytic clearance.
Three structural changes define the molecule. At position 8 an alpha-aminoisobutyric acid residue replaces alanine, which blocks dipeptidyl peptidase-4 cleavage. At position 34 arginine replaces lysine, and at position 26 a lysine carries a C18 fatty diacid attached through a short linker. The fatty chain binds serum albumin, and this albumin association reduces renal filtration and enzymatic attack. The unchanged backbone retains the receptor contacts that produce signalling. The free base has the formula C187H291N45O59 and a molecular weight near 4114 daltons.
Semaglutide is a synthetic peptide of thirty-one amino acids that shares roughly ninety-four percent sequence identity with human glucagon-like peptide-1. Two substitutions resist enzymatic cleavage by dipeptidyl peptidase-4, and a fatty diacid side chain attached through a linker promotes binding to serum albumin. That albumin binding slows renal clearance and extends the circulating half-life from minutes to approximately one week. The structural changes are well established in the published literature. Whether the same modifications affect receptor signalling bias in ways that matter clinically remains an open question.
Pharmacological activity arises from agonism at the glucagon-like peptide-1 receptor, a G protein-coupled receptor expressed in the pancreas, the gastrointestinal tract, and the brainstem. Receptor activation raises intracellular cyclic adenosine monophosphate and enhances insulin release in a glucose-dependent manner, an effect that diminishes when blood glucose concentration is low. Other effects include slowed gastric emptying and hypothalamic satiety signalling. These pathways are described well. Receptor desensitisation rates across tissues, relative to the endogenous hormone, are still under investigation, and reported findings differ between laboratories.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C187H291N45O59 | free base, without counter-ion |
| Molecular weight | About 4114 Da | peptide backbone plus attached lipid chain |
| Plasma half-life | About 165 hours | supports once-weekly dosing in humans |
| Plasma protein binding | Greater than 99 percent | attributed mainly to serum albumin |
| Receptor target | GLP-1 receptor | Gs-coupled, raises intracellular cyclic AMP |
The primary target is the GLP-1 receptor, a class B G protein-coupled receptor expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises intracellular cyclic AMP, which potentiates glucose-dependent insulin secretion and lowers glucagon release when blood glucose is elevated. Signalling in the hypothalamus and brainstem is associated with reduced appetite and slower gastric emptying. Because the insulinotropic effect depends on prevailing glucose levels, the hypoglycaemic risk of the peptide alone is described as low in most study settings. The relative contribution of peripheral and central actions remains an active research question.
Large randomised trials in adults with type 2 diabetes and in adults with obesity have reported reductions in body weight and improvements in several cardiovascular risk markers. One outcome trial found a lower incidence of major adverse cardiovascular events in participants with diabetes and established cardiovascular disease. Gastrointestinal effects such as nausea and vomiting are the most frequently reported adverse events and often diminish over time. Changes in lean body mass during weight loss are an area of ongoing investigation. Effects in adolescents and in pregnancy are less well characterised, and current labelling advises against use during pregnancy.
Two principal therapeutic variants exist under separate regulatory filings, one indicated for glycemic control in type 2 diabetes and one for chronic weight management. Both use the same active molecule; differences lie in formulation strength, titration schedule, and labeling. Regulatory agencies in the United States and European Union approved injectable forms in 2017 and 2018 respectively. An oral tablet formulation received approval later, using a carrier molecule to enhance absorption across the gastric epithelium. Labeling differs by jurisdiction and by indication.
The distinction between established facts and open questions matters here. That the peptide binds the GLP-1 receptor and stimulates insulin release in a glucose-dependent manner is well documented. How individual variability in receptor density, gastric emptying rate, and gut microbiome composition shapes response remains an active research area. Long-term outcomes beyond five years of continuous use are not yet fully characterized in published trials, and several extension studies are ongoing.
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1, a hormone released from intestinal L cells after food intake. The molecule is a 31-amino-acid backbone modified at three positions to resist cleavage by dipeptidyl peptidase-4, the enzyme that degrades native GLP-1 within minutes. A lysine residue at position 26 carries a linker and a C18 fatty diacid, which promotes binding to serum albumin and slows renal clearance. These changes extend the circulating half-life from roughly two minutes to about one week in humans.
== Analysis == A wide variety of techniques can be used to analyze the interfacial layer, often SAXS, NMR, AFM, STM are used, but other methods, like measuring the refractive index can reveal information as well. Small-angle X-ray diffraction provides data about the size and dispersion of the nanoparticles, and gives information about the density of the interfacial layer. Because the amount of scattering is proportionate with the density. On top of this the thickness of the layer can be estimated. However a disadvantage is that SAXS is destructive. AFM and STM measurements can reveal information at atomic resolution about the structure and shape of the interfacial layer. This information is limited to the surface of the nanoparticle, as you can only probe the surface. Another drawback of STM is that it's only applicable if the interfacial layer is conducting. (Solid-state) NMR can be used to study the composition, short range ordering and dynamics in the interfacial layer. The dynamics can be studied over a wide range of timescales, which allows the intermolecular interactions, chemical reactions and transport phenomena to be analyzed.
Deborah Kay Dunn-Walters FMedSci (born September 1963) is a British immunologist who is Professor of Immunology and Associate Dean for Research and Innovation at the University of Surrey. Her research considers B-cell development in healthy ageing and in disease, particularly from the viewpoint of antibody repertoires. During the COVID-19 pandemic, Dunn-Walters focussed on mapping responses to SARS-CoV-2 infection and the development of single cell analyses of the immunological responses to a COVID-19 vaccine. She was a member of the Scientific Advisory Group for Emergencies, and provided the government with scientific advice during the pandemic.
Wherever Marvel Studios plans to take the MCU in the future, it's refreshing to know that its past is expansive and filled with infinite possibilities. Likewise, in his review of Avengers: Endgame, Joe Morgenstern of The Wall Street Journal acknowledged the unique achievement that the Marvel Cinematic Universe had accomplished:
Sources: en.wikipedia.org
==== Transformers ==== The self-attention mechanism enables the model to determine the relative importance of each token in a sequence when predicting the next token, thereby improving contextual understanding. Unlike recurrent neural networks, transformers process tokens in parallel, which improves training efficiency and scalability. Transformers became the foundation for the generative pre-trained transformer (GPT) series developed by OpenAI, replacing traditional recurrent and convolutional models.
=== First treatment === The recommended first treatment is a four- to six-week course combining stretching, foot taping (using a special tape around the foot for supporting the arch) and individually tailored education on footwear and other management options. Reduction in pain and stress involve strengthening foot muscles that support the arches through barefoot exercising, without footwear, compared to exercising in common footwear. Supportive insoles are a common conservative treatment. Insoles that provide arch support and cushioning may reduce strain on the plantar fascia by improving foot alignment and distributing plantar pressure more evenly during standing and walking. This reduction can help alleviate discomfort, particularly in individuals who engage in prolonged standing or repetitive weight-bearing activities.
A macrophagic myofasciitis (MMF) lesion a histopathological finding involving inflammatory microphage formations with aluminium-containing crystal inclusions and associated microscopic muscle necrosis in biopsy samples of the injection site. A MMF "syndrome" refers to a muscle pain or weakness that, when biopsied, often results in the observation of a MMF lesion. It is dubious whether the systemic "syndrome" represents a biological process connected to the local lesion, or even whether it is a specific condition. Most cases are reported in France, where there are more than 600 diagnoses among an immunized population of more than 64 million. The World Health Organization has concluded that
Aden soon became an important transit port and coaling station for trade between British India and the Far East, and Europe. The commercial and strategic importance of Aden increased considerably when the Suez Canal opened in 1869. From then and until the 1960s, the Port of Aden was to be one of the busiest ship-bunkering, duty-free shopping, and trading ports in the world. In 1937, Aden was separated from British India to become a Crown colony, a status that it retained until 1963. It consisted of the port city of Aden and its immediate surroundings (an area of 192 km2 [74 sq mi]). The Aden Settlement, and later Aden Colony, also included the outlying islands of Kamaran (de facto), Perim and Kuria Muria (see map). Prior to 1937, Aden had been governed as part of British India (originally as the Aden Settlement under the Bombay Presidency, and then as a Chief Commissioner's province). Under the Government of India Act 1935 the territory was detached from British India, and was re-organised as a separate Crown colony of the United Kingdom; this separation took effect on 1 April 1937. Through the latter years of its existence, Aden Colony was plagued by civil unrest.
Sources: en.wikipedia.org
Native GLP-1 is a short-lived peptide cleared within one to two minutes by dipeptidyl peptidase-4 and related enzymes. Semaglutide keeps the receptor-binding backbone but adds substitutions and a lipid chain. These changes block the main cleavage site and allow reversible albumin binding, extending the half-life to roughly 165 hours.
Albumin is the most abundant protein in plasma and carries molecules that bear fatty-acid chains. Binding shields the peptide from renal filtration and from peptidases, keeping a circulating reservoir. Slow release from this reservoir produces sustained receptor occupancy and supports infrequent dosing.
The insulinotropic effect is glucose-dependent, meaning secretion increases mainly when glucose is elevated. This property is often described as lowering the chance of hypoglycaemia when the compound is used alone. Other glucose-lowering agents used at the same time can still cause low blood glucose.
It is a glucagon-like peptide-1 receptor agonist, often grouped with the incretin mimetics. Its backbone is modified from the human hormone to resist enzymatic degradation and to bind albumin. These two features distinguish it from the native peptide.